Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070821 | 0.91 | ADAM17 (0.45) | SMN1; SMN2 | |
| SCHEMBL6675011 | 0.89 | CCR1 (0.43) | LMNACCR1ALDH1A1 | |
| SCHEMBL4067999 | 0.86 | ALDH1A1 (0.46) | LMNAPOLBMAPTSMN1; SMN2GAA | |
| SCHEMBL4062732 | 0.85 | POLB (0.39) | HPGDTSHRPOLBMAPTSMN1; SMN2 | |
| SCHEMBL4067750 | 0.84 | TSHR (0.48) | ALOX15LMNAHPGDTSHRPOLB | |
| SCHEMBL4066473 | 0.83 | CTSC (0.36) | LMNAHPGDPOLBSMN1; SMN2CCR1 | |
| SCHEMBL4064274 | 0.83 | CCR1 (0.41) | TSHRCCR1 | |
| SCHEMBL6832277 | 0.83 | CCR1 (0.41) | TSHRCCR1 | |
| SCHEMBL6169667 | 0.83 | CCR1 (0.43) | MAPTCCR1 | |
| SCHEMBL4064042 | 0.83 | CCR1 (0.43) | MAPTCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966443-B1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | ALOX15 215/4885LMNA 4874/4885HPGD 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.